The FDA did NOT grant full approval to the Pfizer

New Post Public Reply Private Reply Replies (1) Message Board
energy_wave
1,579
The FDA did NOT grant full approval to the Pfizer shots

Quote:
August 26, 2021

By Carl Schwitzer

You may have heard that the Pfizer-BioNTech COVID-19 shot received FDA approval this past Monday. Politicians, national health officials, and journalists are breathless with excitement about how this approval will finally induce the remaining "vaccine-hesitant" into stepping forward to receive their jab. The FDA even has a press release on its website about it.

There's just one problem.

If you read the actual letters that the FDA sent to Pfizer on August 23, 2021, you'll see that the FDA did no such thing. In the sense that the term "FDA approval" is generally understood, this drug is not approved by the FDA. It is still under EUA (Emergency Use Authorization). It is still an experimental drug.

The FDA sent two letters. The first one was a letter of BLA (Biologics License Application) approval, and the second was a letter of EUA extension to COMIRNATY.

The BLA approval letter approves Pfizer's application for a license to label its COVID-19 drug with the brand name COMIRNATY. This letter also spells out the terms and requirements for nine additional clinical trials over five years, and yearly status reports, to study the acknowledged occurrences of myocarditis and pericarditis that have followed the administering of the Pfizer shots. This license to label and manufacture is not a full approval of the drug, which clearly is still subject to many years of clinical trials.

The EUA extension letter extends the term of the EUA for the current drug and authorizes (licenses) the experimental use of the brand-name drug COMIRNATY. In the first paragraph on page 2, this letter references the license approval letter. In the second paragraph on page 2, the August 12 EUA is re-issued to include the name-branded drug in the emergency use authorization, and to add "language regarding warnings and precautions related to myocarditis and pericarditis." In the last paragraph on page 4, the EUA nature of the drugs is re-iterated, and COMIRNATY is additionally authorized for use for individuals aged 12 through 15 years.

The mRNA gene therapy shots are still experimental. Mandating them is still wrong — by a wide variety of ethical standards.

Dr. Meryl Nass, M.D. found the truths that the FDA buried in the blather of these letters and offers a theory about why it was done this way. The drug-manufacturers were granted immunity from liability for the drugs produced under the EUAs. The granting of the license re-applies the customary liability for injury and death caused by the product. Pfizer, the health officials, and the politicians get to take a fictitious victory lap for the "approval," while Pfizer-BioNTech continues to stealthily enjoy immunity from product liability because there are many millions of the unlicensed doses on the shelves and in the manufacturing pipeline that will be administered first. The licensed version will not arrive on shelves or be jabbed into arms for many months to come.

Of great concern, considering the factual content of the FDA EUA letters to Pfizer, is the breezy way the press release on the FDA website repeatedly uses the words "approve" and "approval" in reference to the Pfizer drug. If only there were a word for intentionally saying things to the public that do not match reality...

COMIRNATY seems like an unusual name for anything, much less a cutting-edge-technology gene therapy. Out of idle curiosity, I ran the name through an anagram solver. For a result, it gave TIROMANCY, which is divination or prophecy by examining how curds form during the coagulation of cheese. How apropos. That's something I'm willing to try for forecasting the results of the next election!
By Carl Schwitzer

You may have heard that the Pfizer-BioNTech COVID-19 shot received FDA approval this past Monday. Politicians, national health officials, and journalists are breathless with excitement about how this approval will finally induce the remaining "vaccine-hesitant" into stepping forward to receive their jab. The FDA even has a press release on its website about it.

There's just one problem.

If you read the actual letters that the FDA sent to Pfizer on August 23, 2021, you'll see that the FDA did no such thing. In the sense that the term "FDA approval" is generally understood, this drug is not approved by the FDA. It is still under EUA (Emergency Use Authorization). It is still an experimental drug.

The FDA sent two letters. The first one was a letter of BLA (Biologics License Application) approval, and the second was a letter of EUA extension to COMIRNATY.

The BLA approval letter approves Pfizer's application for a license to label its COVID-19 drug with the brand name COMIRNATY. This letter also spells out the terms and requirements for nine additional clinical trials over five years, and yearly status reports, to study the acknowledged occurrences of myocarditis and pericarditis that have followed the administering of the Pfizer shots. This license to label and manufacture is not a full approval of the drug, which clearly is still subject to many years of clinical trials.

The EUA extension letter extends the term of the EUA for the current drug and authorizes (licenses) the experimental use of the brand-name drug COMIRNATY. In the first paragraph on page 2, this letter references the license approval letter. In the second paragraph on page 2, the August 12 EUA is re-issued to include the name-branded drug in the emergency use authorization, and to add "language regarding warnings and precautions related to myocarditis and pericarditis." In the last paragraph on page 4, the EUA nature of the drugs is re-iterated, and COMIRNATY is additionally authorized for use for individuals aged 12 through 15 years.

The mRNA gene therapy shots are still experimental. Mandating them is still wrong — by a wide variety of ethical standards.

Dr. Meryl Nass, M.D. found the truths that the FDA buried in the blather of these letters and offers a theory about why it was done this way. The drug-manufacturers were granted immunity from liability for the drugs produced under the EUAs. The granting of the license re-applies the customary liability for injury and death caused by the product. Pfizer, the health officials, and the politicians get to take a fictitious victory lap for the "approval," while Pfizer-BioNTech continues to stealthily enjoy immunity from product liability because there are many millions of the unlicensed doses on the shelves and in the manufacturing pipeline that will be administered first. The licensed version will not arrive on shelves or be jabbed into arms for many months to come.

Of great concern, considering the factual content of the FDA EUA letters to Pfizer, is the breezy way the press release on the FDA website repeatedly uses the words "approve" and "approval" in reference to the Pfizer drug. If only there were a word for intentionally saying things to the public that do not match reality...

COMIRNATY seems like an unusual name for anything, much less a cutting-edge-technology gene therapy. Out of idle curiosity, I ran the name through an anagram solver. For a result, it gave TIROMANCY, which is divination or prophecy by examining how curds form during the coagulation of cheese. How apropos. That's something I'm willing to try for forecasting the results of the next election!



https://www.americanthinker.com/blog/2021/08/...shots.html
big-wave_surfing_01.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Icahn Faces $225M Q3 Loss, But CVR Deal Shines

Updated Category News Views 30

Icahn Enterprises Stumbles in Q3, Losses Widen When a company's financial report starts with a loss, it's like stepping into a bar fight expecting cheers—you’re bound to get more than you bargained for. Icahn Enterprises L.P.'s third quarter report isn't exactly a rosy picture. We're staring down the barrel of a net loss of $225 million, a sharp contrast to the $287...

Continue Reading
Linker Vision's AI Platform Boosts Urban Planning

Updated Category News Views 72

Now, I've seen a fair share of tech rollouts claiming to change the world, but Linker Vision’s new AI platform, Linker AI Nexa, might actually be onto something real here. Revealed at the Smart City Expo World Congress 2026 in Barcelona, this isn't just another pretty interface—it’s packing some serious firepower with NVIDIA tech. Bringing Physical AI to City...

Continue Reading
SWFI's I20 Summit Spotlights 3,000 Promising Start-Ups

Updated Category News Views 70

Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...

Continue Reading
Speakeasy Dispensary Brings Medical Cannabis to Maysville

Updated Category News Views 33

New Chapter for Maysville: Speakeasy Opens Doors Normally, you'd think of medical cannabis expansions as dry numbers and policies, but with Speakeasy Dispensary making its mark in Maysville, it's not just about business; it's a service to the community. Nestled into 317 W 2nd St, this is more than a simple retail spot. It's about bringing medical options straight to the...

Continue Reading
Neera Tanden's Progressive Vision for 2027 and Beyond

Updated Category News Views 16

Neera Tanden Sets the Stage for 2027 When it comes to politics, everyone’s got their two cents, but Neera Tanden’s unpacking a whole piggy bank of progressive dreams. Set against the backdrop of a freshly reshuffled Congress post-midterms, she’s poised to dish out her roadmap for the future at the National Press Club on November 9. A Gathering of Minds This ain't...

Continue Reading
Synova Global Taps Eventus for Top Trade Surveillance

Updated Category News Views 89

Synova and Eventus: A Powerful Partnership If you've ever traded a share or two, you know the name of the game is risk management. Step into Synova Global's latest move, and you'll see a gamble worth watching closely. This time around, Synova has tapped Eventus to bring their Validus trade surveillance platform into the fold. Now, Eventus and its star player, Validus,...

Continue Reading
M-tron Industries Gears Up for Sonoma Investor Meetings

Updated Category News Views 13

Investors ready for solid insights from M-tron The quiet whispers of impending deals and candid discussions are what really fuel the grind of stock market exchanges. Come November 16, at the Raymond James Investor-Led Sonoma Small Cap Symposium, you can bet your last nickel that M-tron Industries, Inc. (NYSE American: MPTI) will be making waves by doling out their future...

Continue Reading
BAIC FOTON Expands With New Trucks in Africa

Updated Category News Views 88

Innovation in African Mobility Amidst the sparse horizons of Port Elizabeth, South Africa, BAIC FOTON is shifting gears in a big way. They've rolled out a duo of heavy-duty trucks—the GALAXUS R5 and C5—and topped it off with the TUNLAND V PHEV plug-in hybrid pickup. On October 29, the Africa Regional Partner Conference buzzed with talk of 'Driving to Great,' signaling...

Continue Reading
DUPR Teams Up with InBody to Elevate Pickleball Fitness

Updated Category News Views 48

Well, here's a twist in the pickleball world—DUPR and InBody have struck a deal to bring top-notch body composition tech to the ever-expanding universe of pickleballers. They're merging power players from two different worlds to tap into your performance on the court and your wellness off it. Maybe I'm just jaded from too many marketing pitches, but this one could...

Continue Reading
PATEO Drives In-Car AI Forward with NVIDIA Power

Updated Category News Views 97

Revolutionizing In-Vehicle AI with Big Names Boy, driving ain't what it used to be, and PATEO's latest adventure has a lot to do about it. They've hooked up with some major players like NVIDIA and ByteDance to really shake up the in-car AI scene. We're not just talking bells and whistles, but a true reinvention trying to blend AI straight into our daily grind on the road....

Continue Reading
lass="blog__more"> More News Articles